Epidemiologic and Clinical Features of Mpox-Associated Deaths — United States, May 10, 2022–March 7, 2023
Aspen Riser, Allison Hanley, Michael J. Cima, Linda Lewis, Kayla Saadeh, Jemma Alarcón, Lauren Finn, Moon Kim, Jeremy N. Adams, Douglas B. Holt, Amanda Feldpausch, Jessica Pavlick, Andrew English, Marguerite E. Smith, Tyler Rehman, Ronald Lubelchek, Stephanie R. Black, Matthew Collins, Layne Mounsey, David Blythe, Meredith Hodach Avalos, Ellen H. Lee, Olivia Samson, Marcia Wong, B. Denise Stokich, Ellen Salehi, Lynn Denny, Kirsten Waller, Pamela Talley, Julie Schuman, Michael Fischer, Stephen White, Kenneth R. Davis, Ashley Caeser Cuyler, Rabeeya Sabzwari, Robert N. Anderson, Katrina M Byrd, Jeremy A.W. Gold, Shannon Kindilien, James T. Lee, Siobhán O’Connor, Jesse O’Shea, LaTweika A.T. Salmon-Trejo, Raquel Velazquez‐Kronen, Carla Zelaya, William A. Bower, Sascha Ellington, Adi V. Gundlapalli, Andrea M. McCollum, Leah Zilversmit Pao, Agam K. Rao, Karen K. Wong, Sarah Anne J. Guagliardo
Abstract
(1.3 per 1,000 mpox cases) were reported to CDC and classified as mpox-associated (i.e., mpox was listed as a contributing or causal factor). Among the 38 mpox-associated deaths, 94.7% occurred in cisgender men (median age = 34 years); 86.8% occurred in non-Hispanic Black or African American (Black) persons. The median interval from symptom onset to death was 68 days (IQR = 50-86 days). Among 33 decedents with available information, 93.9% were immunocompromised because of HIV. Public health actions to prevent mpox deaths include integrated testing, diagnosis, and early treatment for mpox and HIV, and ensuring equitable access to both mpox and HIV prevention and treatment, such as antiretroviral therapy (ART) (5).